Login / Signup

Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available.

Michael FralickAaron S Kesselheim
Published in: Pharmacoepidemiology and drug safety (2017)
Keyphrases
  • big data
  • adverse drug
  • machine learning
  • deep learning
  • breast cancer risk